Skip to main content
SpringerLink
Log in

Disposition of [4-14C]mofebutazone in the rat

  • Original Papers
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The absorption and elimination of radioactivity after the oral or intraperitoneal administration of [414C]mofebutazone was studied in rats. The blood concentration of radioactivity reached a maximum after about 0.7 h, fell rapidly until about 2 h, and then declined slowly, There was sometimes a second peak between 3–6 h. Elimination of radioactivity in urine and feces was extensive and rapid. Over a 24 h period, 73% of the orally administered radioactivity was eliminated in the urine and 15% in the faeces; most of this was eliminated during the first 8 h (89% of the urine radioactivity, 56% of the faeces radioactivity). In anaesthetized rats with cannulated bile ducts, 94% of the intraperitoneally injected radioactivity was eliminated in the bile over a 6 h period. Most of the radioactivity (about 85%) eliminated in the bile and the urine was in the form of a glucuronide and only small amounts less than 10%, was in the form of mofebutazone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Krohs W. (1965): Pyrazole Derivatives in ‘Analgetics’, edited by G. de Stevens, Academic Press, New York, pp 331–403.

    Google Scholar 

  2. Larsen V., Bredahl E. (1966): The embryotoxic effect on rabbits of monophenylbutazone (Monazan®) compared with phenylbutazone and thalidomide. Acta Pharmacol. Toxicol.,24, 443–455.

    CAS  Google Scholar 

  3. Thune S. (1967): Comparison of phenyl- and monophenylbutazone (Mobutazon®), especially in respect to the incidence of side effects. A double-blind study. Acta Rheumatolog. Scand.,13, 63–80.

    CAS  Google Scholar 

  4. Woodbury J.F.L., Turner W.A., Tiongson R. (1969): Rheumatoid arthritis: comparison of treatment with monophenylbutazone and phenylbutazone. Can. Med. Assoc. J.,101, 801–803.

    Google Scholar 

  5. Scarselli V (1959): Tossicita’ e cinetica dell’eliminazione del 2-fenil, 3,5-diossi, 4-n-butil, pirazolidina comparativamente a quelle del 1,2-difenil-derivato. II Farmaco, Ed. Sei.,14, 347–351.

    CAS  Google Scholar 

  6. Holmen-Christensen H. (1967): Identification and UV spectrophotometric determination of phenylbutazone ana-logues from thin-layer chromatograms, in ‘Scientiae Pharmaceuticae’ Vol. II (Proceedings of the 25th Congress of Pharmaceutical Sciences, Prague, 1965), edited by O. Hanc and J. Hubík. Butterworths, London, pp 152–160.

    Google Scholar 

  7. Büchi J., Ammann J., Lieberherr R., Eichenberger E. (1953): Über neue 3,5-Dioxo-pyrazolidine. Helv. Chim. Acta,36, 75–85.

    Article  Google Scholar 

  8. Taylor E.C., Hawks G.H., III, McKillop A. (1968): Thallium in organic synthesis. I. Alkylation and acylation of β-dicarbonyl compounds. J. Amer. Chem. Soc,90, 2421–2422.

    Article  CAS  Google Scholar 

  9. Schultz O.-E., Mocha M. (1977): DC-Direktauswertung von Monophenylbutazon und das Problem seiner Stabilität in pharmazeutischen Spezialitäten. Pharm. Ztg.,122, 1305–1313.

    CAS  Google Scholar 

  10. Salzmann U. (1971): Zur Dünnschichtchromatographie von l-Phenyl-4-n-butyl-3,5-dioxo-pyrazolidin (Monophenylbutazon). Pharm. Acta Helv.,46, 721–729.

    CAS  PubMed  Google Scholar 

  11. Woodruff M., Polya J.B. (1974): Pyrazolidine-3,5-diones with heterocyclic substituents. I. Preparation of 3-phenyl-1,2,4-triyzolyl derivatives. Aust. J. Chem.,27, 2447–2454.

    CAS  Google Scholar 

  12. Veibel S., Linholter S., Sorensen P. (1958): Pyrazole studies. XI. Oxidation by air of 1:4-disubstituted pyrazolidine-3:5-diones. Acta Chem. Scand.12, 1359–1363.

    Article  Google Scholar 

  13. Woodruff M., Polya J.B. (1975): Pyrazolidine-3,5-diones with heterocyclic substituents. III. Oxidation of 4-monoalkylpyrazolidine-3,5-diones. Aust. J. Chem.,28, 421–426.

    Article  CAS  Google Scholar 

  14. Klemm K., Langenscheid E. (1970): Verfahren zur Herstellung von 2-Butyl-N,N’-diphenyl-malono-monohydrazid und seinen Calcium-, Magnesium- und Aluminiumsalzen. Bundesrepublik Deutschland Offenlegungsschrift 2 055 845.

  15. Shusherina N.P., Levina R.Ya., Lurè M.Yu. (1956): Cyanoethylated ketones in the synthesis of unsaturated δ-lactones. V. Synthesis and properties of unsaturated δ-lactones from monocyanoethylated derivatives of acetone and cyclohexanone. Zhur. Obshchei Khim.,26, 750–755; Chem. Abstr.,50, 1470ld (1956).

    CAS  Google Scholar 

  16. Bridges J.W., Kibby M.R., Williams R.T. (1965): The structure of the glucuronide of sulphadimethoxine formed in man. Biochem. J.,96, 829–836.

    CAS  PubMed  Google Scholar 

  17. Schulte K.E., Rendic S., Henke G., Mrongovius R.I. (1978): Pharmacokinetics and disposition of orally administered [2,3-l4C] succinimide in the rat. Europ. J. Drug Metab. Pharmacokinet.,3, 31–38.

    CAS  Google Scholar 

  18. El-Hawari A.M., Plaa G.L. (1978): Role of the enterohepatic circulation in the elimination of Phenytoin in the rat. Drug Metab. Disp.,6, 59–69.

    CAS  Google Scholar 

  19. Bakke O.M., Draffan G.H., Davies D.S. (1974): The metabolism of phenylbutazone in the rat. Xenobiotica,4, 237–254.

    Article  CAS  PubMed  Google Scholar 

  20. Dean H.G., Donovan B., Rylett P. (1976): The distribution and excretion of,4-C and -’H-labelled 4-prenyl-l,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in the rat. Arzneim.-Forsch.,26, 1574–1581.

    CAS  Google Scholar 

  21. Ludwig G., Ache I.-M. (1973): Untersuchungen mitl4C -markierten Butyl-malonsäure-mono-(l,2-diphenyl-hydrazid)-Calcium (Bumadizon-Calcium). Stoffwechsel und Kinetik. Arzneim.-Forsch.,23, 1226–1231.

    CAS  Google Scholar 

  22. Testa B., Jenner P. (1976): Drug Metabolism: Chemical and Biochemical Aspects. Marcel Dekker Inc., New York. p 200.

    Google Scholar 

  23. Awang D.V.C., Vincent A., Matsui F. (1973): Pattern of phenylbutazone degradation. J.Pharm. Sei.,62, 1673–1676.

    Article  CAS  Google Scholar 

  24. Toft P., Dring L.G., Hirom P.C., Williams R.T., Donetti A., Midgley J.M. (1975): The metabolism of [l4C] prenazone in the rat. Xenobiotica,5, 729–739.

    Article  CAS  Google Scholar 

  25. Seebald H., Forth W. (1977): Absorption of14C-bumadizone-Ca andl4C-phenylbutazone in isolated intestinal segments in vitro and tied-off gastrointestinal sections in vivo of rats and guinea pigs. Arzneim.-Forsch.,27, 624–635.

    CAS  Google Scholar 

  26. Dieterle W., Faigle J.W., Mory H., Richter W.J., Theobald W. (1975): Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan®) in man. Europ. J. Clin. Pharmacol.,9, 135–145.

    Article  CAS  Google Scholar 

  27. Dieterle W., Faigle J.W., Früh F., Mory H., Theobald W., Alt K.O., Richter W.J. (1976): Metabolism of phenylbutazone in man. Arzneim.-Forsch.,26, 572–577.

    CAS  Google Scholar 

  28. Faigle J.W., Dieterle W. (1977): The biotransformation of phenylbutazone (Butazolidin®). J. Internat. Med. Res.,5, Supplement 2, 2–14.

    CAS  Google Scholar 

  29. Sahli M., Ziegler H. (1961): Zur Analytik des 1-Phenyl-4n-butyl-3,5-dioxopyrazolidins. Arch. Pharm. Chem.,68, 186–197.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmazeutische Chemie der Universität Münster, Hittorfstr. 58-62, D-4400, MÜNSTER, Federal Republic of Germany

    V. Bass, R. I. Mrongovius & K. E. Schulte

Authors
  1. V. Bass
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. I. Mrongovius
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. E. Schulte
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bass, V., Mrongovius, R.I. & Schulte, K.E. Disposition of [4-14C]mofebutazone in the rat. European Journal of Drug Metabolism and Pharmacokinetics 5, 201–206 (1980). https://doi.org/10.1007/BF03189465

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189465

Key-words

Search

Navigation